BioMarin PharmaceuticalBMRN

Biotech & innovation · NASDAQ · USA

$54.89

Down 0.6% todayClose Oct 8

Down 7.1% this year and −7.0% since June 26, behind the life science sector at +10.7%. BioMarin Pharmaceutical supplies 1 mapped company and buys from 1.

Market cap: $10.5B
This year: −7.1%
1 year: +0.9%
P/E: 143.4
P/S: 3.1
P/B: 1.7

Price vs the life science sector

since Jun 26BMRNLife science sector, equal weight

Supply chain

1 supplier · 1 customer

Suppliers 1

CRLCharles River Laboratories−0.8%

Customers 1

CORCencora+1.3%

Open the full chain →

About BioMarin Pharmaceutical

Rare genetic disorders define the company. It sells enzyme replacement therapies and Voxzogo for dwarfism, and has taken gene therapy into hemophilia.

Theme exposure

Rare diseaseRare diseasesEnzyme therapyGene therapy

Products

Enzyme replacement therapies
Voxzogo (dwarfism)
Gene therapy (hemophilia)

Competitors

Sarepta Therapeutics
Ultragenyx
Vertex Pharmaceuticals

Risks

Rare-disease market
Gene therapy pricing

Same segment: Biotech & innovation

Innovation-driven biotech companies focused on novel treatment modalities. Segment 3 of 8 in the Medicine, pharma & life science value chain.

AmgenAMGN−1.4%Gilead SciencesGILD+0.2%Vertex PharmaceuticalsVRTX−0.5%ModernaMRNA+0.3%RegeneronREGN−0.3%BiogenBIIB−1.7%Alnylam PharmaceuticalsALNY+0.1%United TherapeuticsUTHR−2.2%

Compare BMRN

Side by side with the largest companies in the same segment.

BMRN vs AMGN BMRN vs GILD BMRN vs VRTX BMRN vs MRNA BMRN vs REGN BMRN vs BIIB

See where BioMarin Pharmaceutical sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →